PharmaJet, Genexine ink deal for needle-free vaccine development

PharmaJet said today it inked a global license agreement with South Korean bioptherapeutics company Genexine to develop and commercialize DNA vaccines using PharmaJet’s needle-free injection system. Through the deal, Genexine will gain access to use both the PharmaJet Stratis and Tropis devices for their Phase I and Phase IIa human clinical studies. The deal also … Continue reading PharmaJet, Genexine ink deal for needle-free vaccine development